ALK and non-small cell lung carcinoma: Rearrangements in the anaplastic lymphoma kinase (ALK) gene are identified in approximately 3–7% of NSCLC cases [15], while alterations involving the ROS1 gene, which encodes a receptor tyrosine kinase, are detected in around 2% of patients [16,17].